Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in primary refractory patients (pts) and in pediatric pts with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) in the phase 2 CheckMate 744 study

被引：0

作者：

Mauz-Koerholz, C. ^{[1
,2
]}

Leblanc, T. ^{[3
]}

Harker-Murray, P. ^{[4
]}

Mascarin, M. ^{[5
]}

Michel, G. ^{[6
]}

Cooper, S. ^{[7
]}

Beishuizen, A. ^{[8
]}

Leger, K. J. ^{[9
]}

Garaventa, A. ^{[10
]}

Buffardi, S. ^{[11
]}

Brugieres, L. ^{[12
]}

Kelly, K. M. ^{[13
]}

Cole, P. D. ^{[14
]}

Drachtman, R. A. ^{[14
]}

Manley, T. ^{[15
]}

Francis, S. ^{[16
]}

Sacchi, M. ^{[16
]}

Daw, S. ^{[17
]}

机构：

[1] Justus Liebig Univ, Univ Hosp, Giessen, Germany

[2] Martin Luther Univ Halle Wittenberg, Fac Med, Halle, Germany

[3] Hop Robert Debre, AP HP, Serv Hematol Pediat, Paris, France

[4] Childrens Hosp Wisconsin, Milwaukee, WI USA

[5] IRCCS Ctr Riferimento Oncol, Aviano, Italy

[6] Hop La Timone, Marseille, France

[7] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[8] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands

[9] Seattle Childrens Hosp, Seattle, WA USA

[10] IRCCS Ist Giannina Gaslini, Genoa, Italy

[11] Santobono Pausilipon Hosp, Naples, Italy

[12] Inst Gustave Roussy, Villejuif, France

[13] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[14] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[15] Seattle Genet, Bothell, WA USA

[16] Bristol Myers Squibb, Princeton, NJ USA

[17] Univ Coll Hosp, London, England

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V610

引用

页码：161 / 162

页数：2